Development of tetrahydroquinazoline-based Fusion protein inhibitor GZMU04 as a therapeutic candidate against respiratory syncytial virus (RSV)

Published: 15 January 2026| Version 1 | DOI: 10.17632/r82nnkntwf.1
Contributor:
Haibin Zhang

Description

Figure S3 of the supporting information

Files

Institutions

  • Guangzhou Medical University

Categories

Nuclear Magnetic Resonance

Licence